CEACAM5 and breast cancer: Furthermore, cancer immune biomarker usage emerged from their ability to reflect patient immune status and his/her eligibility to immune therapy (16), in addition to the lack of sensitivity and specificity of conventional BC diagnostic biomarkers carcinoembryonic antigen (CEA), cancer antigen (CA)125, CA15-3, and alpha-fetoprotein (AFP) (17).